Company Overview of Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel proprietary therapies for the treatment of prostate cancer and other hormonally-driven diseases in the United States. Its lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. The company was founded in 2004 and is based in Cambridge, Massachusetts.
Cambridge, MA 02142
Founded in 2004
Key Executives for Tokai Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $608.5K
Chief Financial Officer
Total Annual Compensation: $201.7K
Chief Medical Officer and Head of Research & Development
Total Annual Compensation: $408.8K
Compensation as of Fiscal Year 2014.
Tokai Pharmaceuticals, Inc. Key Developments
Tokai Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 08:00 AM
May 12 15
Tokai Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 08:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States.
Tokai Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 12 15
Tokai Pharmaceuticals, Inc. announced consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, loss from operations was $13,300,000 compared to $4,892,000 a year ago. Net loss was $13,260,000 or $0.59 basic and diluted per share compared to $4,847,000 or $9.79 basic and diluted per share a year ago. The per share results were skewed by an increase in outstanding shares to 22 million from 495,049. Research and development expenses were $10.6 million compared to $3.6 million in the first quarter of 2014.
Tokai Pharmaceuticals Announces Preclinical Results from the University of Maryland Showing Galeterone and Analogs Inhibit Pancreatic Cancer Cell Growth
Apr 20 15
Tokai Pharmaceuticals, Inc. announced that scientists in the laboratory of Vincent Njar, PhD, at the University of Maryland School of Medicine presented preclinical data showing that galeterone and novel analogs of galeterone inhibited growth, survival and migration of human pancreatic ductal adenocarcinoma (PDAC) cells. These data were presented in a poster presentation titled, 'Galeterone and Its Novel Analogs Induce Profound Anti-Cancer Activities in Human Pancreatic Cancer Cell Lines,' abstract number 1764, at the 2015 American Association for Cancer Research (AACR) in Philadelphia, Pennsylvania. Galeterone and its novel analogs were found to reduce PDAC cell proliferation, cell viability, and colony formation ability using both gemcitabine-naïve and gemcitabine-resistant cell lines and also acted synergistically with gemcitabine to further enhance anti-proliferative effects. Additional in vitro assays demonstrated that galeterone and its analogs reduced tumor cell migration, invasion and reduced MMP9 secretion. At a molecular level, galeterone modulated oncotargets and translational machinery, including the Mink1/2-eIF4E axis.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|